Exchange Traded Concepts LLC Sells 1,130 Shares of Medpace Holdings, Inc. $MEDP

Exchange Traded Concepts LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 41.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,597 shares of the company’s stock after selling 1,130 shares during the period. Exchange Traded Concepts LLC’s holdings in Medpace were worth $821,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of MEDP. Kaufman Rossin Wealth LLC bought a new position in Medpace in the third quarter worth about $395,000. Northwest Wealth Management LLC purchased a new position in shares of Medpace during the 3rd quarter worth approximately $211,000. Brighton Jones LLC grew its holdings in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after acquiring an additional 2,501 shares during the period. Trust Point Inc. raised its position in shares of Medpace by 13.9% in the 3rd quarter. Trust Point Inc. now owns 2,211 shares of the company’s stock worth $1,137,000 after acquiring an additional 270 shares in the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of Medpace by 12.5% in the 3rd quarter. Congress Asset Management Co. now owns 64,695 shares of the company’s stock valued at $33,264,000 after purchasing an additional 7,190 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $567.56 on Monday. The company has a market capitalization of $15.99 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.14 and a beta of 1.43. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26. The firm’s 50 day simple moving average is $579.62 and its two-hundred day simple moving average is $482.65.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same period in the previous year, the business earned $3.01 earnings per share. The business’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MEDP. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Mizuho boosted their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Finally, Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $490.82.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.